Phenotypic Evolution of Therapeutic Salmonella enterica Serovar Typhimurium after Invasion of TRAMP Mouse Prostate Tumor by Choe, Elizabeth et al.
doi:10.1128/mBio.01182-14.
 5(4): .mBio. Mouse Prostate Tumor
 Serovar Typhimurium after Invasion of TRAMPenterica
SalmonellaPhenotypic Evolution of Therapeutic 2014. 
Eisenstark
Elizabeth Choe, Robert A. Kazmierczak and Abraham
 
 
Mouse Prostate Tumor
Typhimurium after Invasion of TRAMP 
 SerovarSalmonella enterica
Phenotypic Evolution of Therapeutic 
 http://mbio.asm.org/content/5/4/e01182-14.full.html
Updated information and services can be found at: 
REFERENCES
 http://mbio.asm.org/content/5/4/e01182-14.full.html#ref-list-1
This article cites 33 articles, 14 of which can be accessed free at:
CONTENT ALERTS
 more>>article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this
 
 http://journals.asm.org/subscriptions/To subscribe to another ASM Journal go to: 
 http://mbio.asm.org/misc/contentdelivery.xhtml
Information about Print on Demand and other content delivery options: 
 http://mbio.asm.org/misc/reprints.xhtmlInformation about commercial reprint orders: 
 
m
bio.asm
.org
 o
n
 O
ctober 14, 2014 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
 
m
bio.asm
.org
 o
n
 O
ctober 14, 2014 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
Phenotypic Evolution of Therapeutic Salmonella enterica Serovar
Typhimurium after Invasion of TRAMP Mouse Prostate Tumor
Elizabeth Choe,a,b Robert A. Kazmierczak,b,c Abraham Eisenstarkb,c
Massachusetts Institute of Technology, Cambridge, Massachusetts, USAa; Cancer Research Center, Columbia, Missouri, USAb; University of Missouri—Columbia, Columbia,
Missouri, USAc
ABSTRACT Salmonella has been of interest in cancer research due to its intrinsic ability to selectively target and colonize within
tumors, leading to tumor cell death. Current research indicates promising use of Salmonella in regular administrations to re-
move tumors in mouse models while minimizing toxic side effects. However, selection of mutants during such long-term tumor
colonization is a safety concern, and understanding selection of certain phenotypes within a tumor is an important consider-
ation in predicting the long-term success of bacterium-based cancer treatment strategies. Thus, we have made an initial exami-
nation of selected phenotypes in a therapeutic Salmonella enterica serovar Typhimurium population developed from an archival
wild-type LT2 strain and intraperitoneally injected into a 6-month-old TRAMP (transgenic adenocarcinoma of mouse prostate)
mouse. We compared the original injected strain to isolates recovered from prostate tumors and those recovered from the spleen
and liver of non-tumor-bearing TRAMPmice through phenotypic assessments of bacteriophage susceptibility, motility, growth
rates, morphology, andmetabolic activity. Tumor isolate traits, particularly the loss of wild-type motility and flagella, reflect the
selective pressure of the tumor, while the maintenance of bacteriophage resistance indicates no active selection to remove this
robust trait. We posit that the Salmonella population adopts certain strategies to minimize energy consumption andmaximize
survival and proliferation once within the tumor. We find these insights to be nonnegligible considerations in the development
of cancer therapies involving bacteria and suggest further examinations into the evolution of therapeutic strains during passage
through tumors.
IMPORTANCE Salmonella is of interest in cancer research due to its intrinsic abilities to selectively target, colonize, and replicate
within tumors, leading to tumor cell death. However, mutation of strains during long-term colonization within tumors is a
safety concern, and understanding their evolution within a tumor is an important consideration in predicting the long-term suc-
cess of bacterium-based cancer treatment strategies. Thus, we have made an initial examination of phenotypically diverse Salmo-
nella colonies recovered from a therapeutic Salmonella strain that we developed and injected into prostate tumor-bearing mice.
We compared the bacteriophage susceptibility, motility, growth rates, morphology, andmetabolic activity of the original thera-
peutic strain to those of strains recovered from prostate tumors of tumor-bearing mice and the liver and spleen of non-tumor-
bearing mice. Our results suggest that the Salmonella population adopts certain strategies to minimize energy consumption and
maximize survival and proliferation once within the tumor, leading to phenotypic changes in the strain.
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Current bacterium-based cancer therapy research is exploringthe use of Salmonella bacteria which, when injected into
tumor-bearing models, preferentially invade and replicate within
tumor tissues, subsequently inhibiting their growth or destroying
them entirely (1, 2). Importantly, these bacteria can penetrate
deep within a tumor and, as facultative anaerobes, thrive in both
hypoxic and oxygen-containing areas in the tumor environment.
The development of a successful bacteriotherapy could lead to
cancer treatments with high tumor-targeting specificity and pre-
cision, avoiding the often negative side effects of nonspecific can-
cer treatments resulting from destruction of healthy cells and tis-
sue. Salmonella enterica serovar Typhimurium (S. Typhimurium)
has proven to be a promising cancer therapeutic candidate due to
its tumor-targeting and killing abilities (2, 3). Researchers have
developed S. Typhimurium strainswith reduced toxicity to reduce
or eliminate the septic side effects often experienced in several
animal hosts; one of these strains successfully colonized nonre-
sponsive tumors in phase I human clinical trials (4). Despite the
lack of adequate tumor regression observed in clinical trials for
reasons outlined in published reports (4, 5), these findings have
demonstrated the potential use of bacteria in cancer therapy and
its short-term safety in humans, and S. Typhimurium remains an
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excellent candidate for cancer therapy either by itself or as a deliv-
ery vector (6–8) due to its extreme tumor-homing abilities even in
advanced metastases (3).
Research is now shifting to implementing regular administra-
tions of low Salmonella doses to effectively eliminate tumors in
mousemodels whileminimizing the incidence of toxic side effects
(3, 9, 10). Investigators at the Cancer Research Center (CRC; Co-
lumbia, MO) have engineered therapeutic strain CRC2631 (Ta-
ble 1), derived from archival, wild-type S. Typhimurium LT2 kept
in sealed agar stabs for over 40 years. Genetic manipulation using
phage transduction and recombineering was employed to mini-
mize the septic side effects of wild-type Salmonella strains while
preserving their tumor-targeting and killing capabilities. A strain
that preferentially targeted transgenic adenocarcinoma of mouse
prostate (TRAMP) mouse prostate tumors rather than normal
Salmonella reservoirs of liver and spleen at ratios of 1,000:1 during
a 24-h incubation period was isolated (11). Initial low-dosage
studies established that weekly, low-dose injections of CRC2631
do not produce ill effects in immunocompetent mice and delay
the mortality of TRAMPmice (R. Kazmierczak and A. Eisenstark,
unpublished data). While clinical trials and murine research ad-
dress toxicity and extension of survival, an evaluation of the mu-
tability of therapeutic strains during colonization as a consider-
ation for clinical safety and maintaining clinical effects has yet to
be explored in research. Here, we report our phenotypic compar-
ative assessments of the therapeutic strain (CRC2636, a derivative
of CRC2631 that expresses red fluorescent tracer protein) before
and after recovery either from the prostate tumor of tumor-
bearing mice or from the liver and spleen of non-tumor-bearing
mice as it affords insight into the evolutionary process of thera-
peutic S. Typhimurium inmurine prostate tumors, the specificity
of the tumor’s selective pressures, and the safety of the long-term
use of the therapeutic strain.
RESULTS
Therapeutic strains maintain bacteriophage resistance during
passage throughprostate tumor.With the exceptionofCRC2652
sensitivity to phage P283, the Salmonella isolates recovered from
TABLE 2 Bacteriophage susceptibility of strains
Isolate source CRC stock no.
Reaction of straina:
ES-18 O-1 P22 P162 P165 P282 P283
LT2       
1674       
2636       
Prostate tumor 2652       P
2653       
2654       
Liver isolate (nontumor) 2835      P P
2836      P P
Spleen isolate (nontumor) 2837      P P
2838      P P
a, complete clearing;, no lysis; P, partial or faint lysis; n 3 trials.
TABLE 1 S. Typhimurium strains and phage isolates used in this studya
CRC
stock no. Strain or phage information and history
Ampicillin
resistance
LT2 Wild-type S. Typhimurium strain, characterized in reference 29 No
1674 Derived from LT2 strain; hisD2550 rpoS; characterized further in reference 30 No
2631 Original therapeutic S. Typhimurium strain injected into TRAMP mice; CRC1674 aroA::Tn10 rfaH::pKD4
thyA::pKD4, where CRC1674 is LT2 hisD2550 (archived 1958, “resuscitated” 1999)
No
2636 CRC2631 that contains pRSET-mCherry plasmid (bla, mCherry) for fluorescence studies; characterized further in
reference 11
Yes
2652 S. Typhimurium recovered from prostate tumor of tumor-bearing TRAMP mouse 3 days after injection with 2636 Yes
2653 S. Typhimurium recovered from prostate tumor of tumor-bearing TRAMP mouse 3 days after injection with 2636 Yes
2654 S. Typhimurium recovered from prostate tumor of tumor-bearing TRAMP mouse 3 days after injection with 2636 No
2835 S. Typhimurium recovered from liver of non-tumor-bearing TRAMP mouse 21 h after injection with 2636 Yes
2836 S. Typhimurium recovered from liver of non-tumor-bearing TRAMP mouse 21 h after injection with 2636 Yes
2837 S. Typhimurium recovered from spleen of non-tumor-bearing TRAMP mouse 21 h after injection with 2636 Yes
2838 S. Typhimurium recovered from spleen of non-tumor-bearing TRAMP mouse 21 h after injection with 2636 Yes
2754 Phage-free S. Typhimurium strain received from A. Segall; SDT2739 S. enterica serovar Typhimurium LT2MA8507
(Gifsy-1 Gifsy-2 Fels-2) Fels-1::frt; characterized further in reference 31
No
ES18 S. Typhimurium-specific bacteriophage characterized in reference 32
O-1 S. Typhimurium-specific bacteriophage characterized in reference 32
P22 S. Typhimurium-specific bacteriophage characterized in reference 32
P162 Lilleengen bacteriophage (lyophilized); STM-30; characterized in reference 33
P165 Lilleengen bacteriophage (lyophilized); STM-31; characterized in reference 33
P282 Fels-1, Gifsy-2 supernatant collected by CRC in 2006
P283 Fels-2, Gifsy-2 supernatant collected by CRC in 2009
a Isolates 2652 to 2653 were recovered from the same mouse; isolates 2835 to 2838 also were recovered from the same mouse.
Choe et al.
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the prostate tumormaintain the phage resistance profile observed
in the original, injected, therapeutic strain CRC2636 (Table 2).
However, strains recovered from non-tumor-bearingmice exhib-
ited a slight loss of phage resistance andwere slightly susceptible to
P282 and P283. Preliminary assays with 2 additional strains from
healthy mice showed the same patterns as those with CRC2835
and CRC2837 (E. Choe, unpublished data).
Isolates recovered from tumors exhibit lower growth rates
and delayed swarming phenotypes. Figure 1 illustrates the phe-
notypic difference in average growth rates—as measured by tur-
bidity levels over time and viable plate counts—revealed by a com-
parison of tumor-bearing isolates and non-tumor-bearing
isolates. Compared to the original injected parent strain CRC2636
and isolates from non-tumor-bearing mice, two of the three iso-
lates recovered after passage through prostate tumors exhibited
slower-changing optical density (OD) during the first 7 h of
growth.One tumor-bearing isolate grew similarly to theCRC2636
parent strain. Isolates from non-tumor-bearing mice demon-
strated more rapid growth than did the parent strain. However,
turbidity reached comparable levels after overnight growth,
though liver and spleen isolate cultures continued to have slightly
higher turbidity. Similarly, a stark difference in motility ring de-
velopment was observed (Table 3), as swarming in tumor isolates
was delayed by as much as 48 h before the expansion of the mo-
tility ring began (though colonization and growth could be ob-
served in the area of inoculation after the first day). However, as
with the growth curve assessments, once the swarming began, the
strains rapidly overtook the dish. Isolates recovered from healthy
mice appeared to grow more rapidly than the original injected
strain and to swarm on a level comparable to, if not slightly lower
than, that of the original strain.
Isolate population recovered from tumor exhibits loss of fla-
gella. Microscopy revealed that all examined isolates recovered
from tumor-bearing mice lacked flagella, unlike the original ther-
apeutic strain and most of the isolates from healthy mice (Fig. 2).
When tested on motility agar, all strains were motile (Table 3).
Tumor isolates also appeared to exhibit greater size variability
between strains.
Isolates recovered from tumors exhibit varied carbon-
containing substrateutilizationand lossof sucrosemetabolism.
Incubation in ESMicroPlate (Biolog) plates revealed variousmet-
abolic profiles of substrate utilization, including loss and gain of
utilization by both tumor isolates and healthy isolates compared
to the original strain (Table 4). Of note are the loss in sucrose
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FIG 1 Assessment of strain growth rate averages via optical density or viable plate count versus incubation time. Overnight cultures were diluted to an OD of
0.05 for initial spectrophotometer readings. Optical density readings were performed every hour for 7 h, and culture dilutions followed by viable plate counting
were performed every other hour for 7 h. Growth curves for strains are colored as follows: parental strains (LT2 and CRC1674), green; injection strain
(CRC2636), blue; tumor-recovered strains (CRC2652,CRC2653, andCRC2654), red; strains recovered from liver or spleen (CRC2835,CRC2836,CRC2837, and
CRC2838), black.
TABLE 3 Average swarming diameter of strains on motility agar
Isolate source CRC stock no.
Diam score at timea:
24 h 48 h 72 h
LT2 7 33 
1674 7  
2636 2 32 
Prostate tumor 2652 2 19 33
2653 2 10 23
2654 1 12 23
Liver isolate (nontumor) 2835 5  
2836 4 33 
Spleen isolate (nontumor) 2837 4 32 
2838 4 33 
a Swarming diameters were assigned a score designating a factor by which the smallest
diameter measurement taken at 24 h (strain 2654) needed to be multiplied to reach the
average swarming diameter of the given strain (n 3). designates overgrowth of the
agar plate (a score of 34), after which measurements could not be taken.
Evolution of Therapeutic Salmonella in Prostate Tumor
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utilization by CRC2653 and CRC2654 (tumor isolates) and the
overall variability in substrate utilization among tumor-bearing
isolates.
DISCUSSION
This study seeks to begin a dialog on the selective environments of
tumors in order to improve therapeutic bacteria, ensure patient
safety during clinical use, and maintain therapeutic efficacy. We
sought to discover what traits a tumor environment selects for or
selects out after successful invasion by a large population of ther-
apeutic bacterial cells. The initial isolates recovered from the pros-
tate tumor maintained their bacteriophage resistance, while those
from the liver and spleen lost their resistance to some phage. We
find this to be a promising attribute of our therapeutic strain, as it
illustrates not only its phenotypic robustness under physiological
conditions in the tumor but also its potential compatibility with
current therapeutic approaches that incorporate bacteriophages
for their antitumor usage or for their ability to display peptides for
anticancer use (12). Our therapeutic strain CRC2631 includes the
deletion of rfaH, which changes the nature of the cell membrane
by reducing the amount of available wild-type lipopolysaccharide
(LPS) and dramatically reducing phage susceptibility, as many
FIG 2 Salmonella isolatemorphology. Isolates were recovered from the following environments: liquid culture (a to c), tumor (d to f), liver (g and h), and spleen
(i and j). Strainswere viewed using transmission electronmicroscopy under negative stainingwith 4%uranyl acetate on carbon-coated copper grids and included
LT2 (bar, 1 m) (a), CRC1674 (bar, 0.5 m) (b), CRC2636 (bar, 0.5 m) (c), CRC2652 (bar, 1 m) (d), CRC2653 (bar, 0.5 m) (e), CRC2654 (bar, 0.5 m)
(f), CRC2835 (bar, 1 m) (g), CRC2836 (bar, 2 m) (h), CRC2837 (bar, 1 m) (i), and CRC2838 (bar, 1 m) (j).
Choe et al.
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phage bind to bacterial LPS before infection (13). The mainte-
nance of phage resistance in tumor-bearing isolates suggests con-
servation of the rfaH deletion, and PCR of the rfaH gene per-
formed on all strains confirmed conservation of this deletion
among all strains (R. Kazmierczak, unpublished data). The slight
susceptibility of non-tumor-passaged strains suggests that passage
through healthy mice is affecting phage susceptibility indepen-
dently of rfaH, which could be confirmed via silver staining to
determine potential differences in LPS profiles.
More intriguing is the loss of flagellar structures and overall
decreased motility and proliferation rates of isolates recovered
from tumor-bearing mice. Flagella and swarming are considered
essential for bacterial signaling systems and efficient infection of
hosts (14, 15).However, we observed that tumor isolates exhibited
a slime production on motility plates even when motility rings
were unapparent. We attribute this slime to production of acidic
polysaccharides, which act as biosurfactants to facilitate move-
ment (16) andmay serve a role in cell-to-cell communication (17,
18).With S. Typhimurium being a Gram-negative bacterium, it is
possible that the tumor-bearingmouse isolates are expressing sig-
naling molecules (15). Cells in these strains may wait to swarm or
even proliferate until a quorum signal is sensed by the popula-
tion—an adaptation to the volatile and nutrient-changing envi-
ronment of the tumor. If quorum sensing, these bacteria would
still be able to create biofilm formations on the tumor cell surfaces
despite their lack of observable flagella (19), as they are stillmotile.
It is important to note that Salmonella bacteria need not bemotile
in order to be virulent (20); however, while the tumor isolates
lacked visible flagella, they were able to move on motility agar,
albeit they were slow to do so. Alternatively, successful motility
after a lag period coupled with high slime production suggests
activation of the Rcs phosphorelay signaling system that inhibits
flagellar synthesis while simultaneously increasing capsular poly-
saccharide production (18). In order to prevent low growth rates
from confounding the motility assessment, we observed swarm-
ing diameters of cultures that had been taken from the actively
migrating periphery of motility plates from the previous day.
Thus, we observe lower motility and overall lower growth rates of
tumor-bearing isolates as separate phenotypes. It is notable that
one tumor-bearing isolate, CRC2652, maintained rapid growth
throughout the 7-h observation period. It is possible that there is
allowable diversity in proliferation rates in the tumor microenvi-
ronment as a means of maximizing survival through rapid gener-
ation of advantageous mutants. We hypothesize that once the
strain is able to penetrate into the tumor, the tumor selects for cells
in which the flagellar biosynthesis can be suppressed to reduce
unnecessary energy consumption.More importantly, the popula-
tion may be abandoning flagella as a means to evade the immune
system, as flagella are known to pose a liability for bacteria during
infection (21). We do not anticipate this to be of concern, as the
strain itself remains attenuated due to the auxotrophicmutations,
though future studies could explore the toxicity of recovered
strains in 50% lethal dose (LD50) studies; additional attenuating
mutations may be necessary for the development of clinical
strains. While other studies have demonstrated enhanced tumor
colonization by the use of flagella (22), our direct observations
indicated repression of the flagellar phenotype 3 days after tumor
colonization. This indicates that genetic manipulation of the fla-
gellar mechanisms may be an advisable technique to enhance
therapeutic value. We acknowledge that differences in incubation
times between passage through tumor-bearing (3 days) and
TRAMP-negative (21 h) mice could be a confounding variable in
the analysis of flagellar presence in the population, but the non-
tumor-bearing mice cleared the strain from the body too rapidly,
presenting an unavoidable experimental constraint. Since S. Ty-
phimurium colonization and proliferation in the tumor environ-
ment occur rapidly (within 15 h) under in vivo conditions (23), we
believe that the major selective forces establishing the tumor mi-
croenvironment as different from the host environment occur
within the first 20 h of incubation, thus minimizing the impact of
dissimilarities between incubation times on observed differences
in bacterial phenotypes. In future studies, we will measure the
number of S. Typhimurium generations that pass during this dif-
ference in time to quantify and characterize the additional selec-
TABLE 4 Variation in carbon-containing substrate utilization by isolates
Typing Substrate
Utilization by straina:
2636
2652 (tumor
isolate)
2653 (tumor
isolate)
2654 (tumor
isolate)
2835 (liver
isolate)
2837 (spleen
isolate)
Salmonella Sucrose      
Adonitol      
Glycolic acid      
Glyoxylic acid      
Phenylethyl amine      
E. coli Citric acid      
m-Inositol      
D-Threonine      
1,2-Propanediol      
m-Tararic acid      
Tricarballylic acid      
Tyramine      
None Formic acid      
Acetic acid      
Acetoacetic acid      
Methyl pyruvate      
2-Amino ethanol      
a Data were not collected for LT2, 1674, 2836, and 2838.
Evolution of Therapeutic Salmonella in Prostate Tumor
July/August 2014 Volume 5 Issue 4 e01182-14 ® mbio.asm.org 5
 
m
bio.asm
.org
 o
n
 O
ctober 14, 2014 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
tive pressure that could be arising due to this experimental con-
straint. We propose that these observed phenotypic differences
are a result of an environmental selection for particular pheno-
types and not randomly arisingmutations of the injected bacterial
population. Recovery of a majority of S. Typhimurium isolates
with lower growth rates argues for selection in the tumor, since
slow growth is a phenotype that one would normally expect to be
found in a minority of the bacterial population.
The Biolog substrate plate assays revealed variability in sub-
strate utilization among all of the S. Typhimurium strains exam-
ined. In particular, some tumor isolates lacked sucrose and adon-
itol metabolism. We attribute this variability and the loss of some
substrate utilization by tumor isolates to selection pressures of the
changing tumor environment during Salmonella-induced necro-
sis. Strains may be deriving nutrients from dying tumor cells, al-
tering the metabolic profile of the Salmonella population. The
high rate of glycolysis and its subsequent by-products in tumors
(or products of the Warburg effect, where cancer cells depend
heavily on glycolysis for energy production [24]) creates an avail-
able nutrient profile that is distinct from those of other environ-
ments of S. Typhimurium, which could be applying pressures that
maintain the glycolic acid and glyoxylic acidmetabolism in tumor
isolates (25). Additionally, it has been shown that particular DNA
motifs and promoters for metabolic utilization are preferentially
upregulated in tumors (26), which may be affecting the changed
metabolic profile of the population that inhabits the prostate tu-
mor. These results emphasize the impact that physiological con-
ditions have on eventual strain metabolism, as illustrated in the
differences in substrate utilization in Table 4. Tumors also exhibit
a gradient of metabolites (27), which would favor metabolic di-
versity within a population invading a tumor. Variability may be
permissible or even favorable in terms of metabolic utilization of
substrates for survival, whereas in the healthy host, deviants from
allowable metabolic utilization are selected out of the system.
Overall, we posit that this variability, along with the trends such as
bacteriophage resistance maintenance, loss of flagella, lower
growth rates, and changed substrate metabolism, illustrates vari-
ous strategies adopted by the Salmonella population—under the
selective pressure of the prostate tumor—to optimize the balance
between minimizing energy consumption and maximizing sur-
vival and proliferation within the tumor.
Recommendations for further studies.Wepresent these find-
ings as an initial assessment of phenotypic changes that can occur
to a therapeutic bacterial population during passage through a
tumor and also acknowledge that the relatively small samples of
isolates studied may not represent the breadth of evolutionary
changes occurring within the population. Thus, to boost the sta-
tistical rigor of the claims made in this study, our next line of
investigation is repeating these assays with a wider range of strain
isolates from several TRAMPmice, in addition to the studies that
we are pursuing as indicated in our discussion. Additionally, be-
cause the therapeutic use dictated that we inject the mice with a
relatively small number of bacteria, which likely had little geno-
typic diversity, it is important to assess the number of cells to
which the original population grew. In addition to assessing gen-
eration time as previously discussed, we also propose injecting
~105 cells into a tumor sample of known weight, incubating the
sample overnight, and performing viable plate counts in the in
vitro sample as a way of measuring the potential bacterial growth
that a given amount of tissue could support and understanding
how spontaneous mutations to create a diverse population could
undergo natural selection. Initial explorations of this nature have
already occurred, as described in this observation. To best assess
the selection pressures of the tumor environment and how they
may impact patient safety when tumors are treated with clinical
Salmonella, we suggest a study in which all cells from the mouse
tumor are collected and Salmonella strains are sorted via
fluorescence-activated cell sorting (FACS), fromwhich strains can
be placed in the Biolog plates for a more exhaustive metabolic
assay. This will include the extraction and analysis of Salmonella
fromnon-tumor-bearing liver, spleen, and prostate tissue, if pres-
ent. Alternatively, the sorted cells may also be directly sequenced
or used to extract mRNA to create a Salmonella population tran-
scriptome profile to compare metabolic data. Characterizing
changes in the Salmonella population genome, transcriptome, or
proteomes would be of particular importance because we have
examined only the phenotypically different colonies of Salmonella
and therefore it is likely that we have missed relevant phenotypes
that do not produce different colony morphologies in rich me-
dium. We find these assays to be valuable in their potential to
monitor the rate and stages of metabolic change in the bacterial
population within the tumor environment over time, give insight
into the evolution of the bacterial population as its environment
changes due to Salmonella-induced necrosis of tumor cells (and
subsequent environmental pressures), and possibly shed light on
the mechanisms of tumor destabilization taking place during tu-
mor inoculation and persistence (for example, by consuming or
altering molecules that inhibit the immune system in localized
tumor regions). A longer-term tracking of tumor-associated
strains (longer than 3 days) could reveal properties of long-term
selective pressures. Injecting mice with Salmonella, sacrificing
them on each progressive day, and examining harvested samples
would provide insight into the average length of Salmonella per-
sistence in the tumor-bearing mouse and the phenotypic traits
that the tumormicroenvironment selects for on a long-term scale.
Finally, to address safety concerns more deliberately, harvested
isolates may be injected back into TRAMPmice and other cancer
models for toxicity studies, and efficacy may be further addressed
via invasion assays by coincubation of isolates from tumor-
bearingmice and healthymice in in vitro prostate cancer cell lines.
MATERIALS AND METHODS
Bacterial strains and culturing methods. S. Typhimurium strains de-
rived fromwild-type LT2 were used in this study. Table 1 shows complete
strain information. All S. Typhimurium strains were grown on nutrient
Luria-Bertani (LB) agar plates (25 g/liter LBpowder, 15 g/liter agar [Fisher
BioReagents] in deionized water) supplemented with 200g/ml thymine
(Acros Organics) at 37°C overnight. Plates for ampicillin-resistant strains
included an additional 50g/ml ampicillin (Sigma). Strainswere cultured
in liquidmediumby stab-inoculating 3ml LB broth (25 g/liter LB powder
in deionized water supplanted with 200g/ml thymine and an additional
50g/ml ampicillin, if required)with single colonies and incubating them
in a 37°C water bath shaker. For antibiotic resistance studies, strains were
cultured on LB-thymine plates and liquid medium was supplemented
with 50 g/ml ampicillin, as applicable.
Injection procedures and harvesting/recovery of S. Typhimurium.
Male C57B16-Tg (tumor necrosis factor [TNF]-receptor-related
apoptosis-mediated protein) 8247Ng/J (TRAMP) mice (Jackson Labora-
tory; as characterized in reference 28) aged 6 to 12 months were used to
collect tumor-passaged and non-tumor-passaged Salmonella. All Univer-
sity of Missouri (Columbia, MO) institutional guidelines for animal care
and use were followed. Overnight cultures of CRC2636 were grown in
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100ml of liquidmedium. The culture was centrifuged and resuspended in
1 phosphate-buffered saline (PBS) (Fisher BioReagents), from which
1 ml was then serially diluted into PBS to a concentration of 106 CFU/ml.
Tumor-bearing and non-tumor-bearing mice were injected intraperito-
neally with 0.1 ml of 106 CFU/ml CRC2636, and the remaining solution
was used for viable plate counts on nutrient plates to determine howmany
bacteria were injected. Genitourinary prostate tumor samples from
tumor-bearing mice were collected 3 days after injection; spleen and liver
samples fromnon-tumor-bearingmicewere collected 21 h after injection.
Samples were homogenized in PBS, serially diluted, and then plated
on nutrient plates and incubated at 37°C to isolate individual colonies for
further characterization. Two tumor-bearing mice and two healthy con-
trol mice were used to collect samples; all bacterial samples from tumors
described in this paper came from a single tumor isolate.
Bacteriophage susceptibility assays. Sensitivity to phage was assessed
by adding 5 l of each phage to Evans blue uranine (EBU) green acidity
differential plates (5 g/liter yeast extract [Fisher], 10 g/liter tryptone [BD],
2.5 g/liter glucose [Fisher], and 15 g/liter agar in deionized water, with the
addition of 1.25ml/liter 1% Evans blue [Aldrich], 2.5ml/liter 1% uranine
[Sigma], and 20ml/liter 25%K2HPO4 [Fisher] after autoclaving) covered
in a mixture of 3 ml top agar (6.5 g/liter agar, 5 g/liter tryptone-peptone
[Difco], 24.4 g/liter LB powder in deionized water) and 200 l of the S.
Typhimurium strain being assessed. Lysis patterns on plates were exam-
ined after a 24-h incubation period at 30°C and are indicated in Table 2.
The six phages used in this study were chosen after preliminary superna-
tant streak testing revealed the most consistently lysing phage out of an
initial set of 20 different phages. ES-18, known to consistently lyse S.
Typhimurium, was used as a control phage in order to ensure that all
recovered strains were indeed S. Typhimurium. All phage were grown on
S. Typhimurium strain CRC2754 (Table 1 gives strain information) with
broth cultures centrifuged at 4,200 rpm for 17 min. The supernatant was
poured into glass vials to which chloroform was added. Assays were per-
formed in triplicate.
Motility assays. Petri dishes containing semisolid motility agar (25%
top agar [6.5 g/liter agar, 5 g/liter tryptone-peptone, 24.4 g/liter LB pow-
der in deionized water], 75% soft agar containing 2 g/liter agar, 7.5 g/liter
tryptone-peptone in deionized water) were stab-inoculated in the center
with liquid cultures of each strain, placed in boxes containing water as a
moisture source, and incubated at 37°C. After 24 h, new motility plates
were stab-inoculated in the center with cultures taken from the outer
periphery of the motility ring from the previous day. Assays were per-
formed in triplicate; the average diameter of strain growth was noted at
various time points as indicated in Table 3.
Growth rates. Comparative growth rates of tumor-bearing S. Typhi-
murium isolates and non-tumor-bearing isolates were assessed by mea-
suring the optical density (OD) of each strain at hourly intervals. Single
colonies were picked from thymine-supplemented LB plates and cultured
in 3 ml LB-thymine broth in a 37°C shaker overnight. All samples were
diluted to an OD of 0.05 in 10 ml thymine-supplemented LB broth and
placed in a 37°C shaker; 1-ml samples were measured in a spectropho-
tometer every hour for 7 h. Viable plate count dilutions were performed at
0, 1, 3, 5, and 7 h to obtain CFU/ml data on thymine-supplemented LB
plate medium. Growth rate determination is the result of at least two
independent assays.
Transmission electron microscopy. Isolate morphology was exam-
ined by centrifuging 3ml of overnight cultures at 4,000 rpm for 5min and
resuspending them in 3ml deionized water twice. Formicroscopy, 4l of
the resuspension was applied to carbon-coated films on copper grids and
negatively stained using 4% uranyl acetate. Specimens were viewed using
a JEOL-1400 transmission electron microscope located in the University
ofMissouri—Columbia’s ElectronMicroscopy Core Facility.Microscopy
images are shown in Fig. 2.
Metabolic utilization assays.Normal saline was inoculated with 24-h
cultures grown on Trypticase soy agar plates (BD) (30 g/liter Trypticase
soy broth, 15 g/liter agar, where soy broth components included 17 g/liter
pancreatic digest of casein, 3 g/liter papaic digest of soybeanmeal, 5 g/liter
NaCl, 2.5 g/liter K2PO4, and 2.5 g/liter dextrose) fromwhich 150l of the
inoculated saline at 53% to 59% turbidity was transferred into each of the
96 wells (each containing a different carbon substrate) of an ES Micro-
Plate plate (Biolog; now available as PM-1 MicroPlate), and substrate
utilization was observed after 24 h at 37°C.
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